Predictions
Biogen Inc.
Start price
Target price
Perf. (%)
€194.35
27.04.24
27.04.24
€200.00
27.04.25
27.04.25
5.58%
12.05.24
12.05.24
Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Biogen Inc.
Start price
Target price
Perf. (%)
€194.35
27.04.24
27.04.24
€200.00
27.04.25
27.04.25
5.58%
12.05.24
12.05.24
Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Biogen Inc.
Start price
Target price
Perf. (%)
€194.35
27.04.24
27.04.24
€200.00
27.04.25
27.04.25
5.58%
12.05.24
12.05.24
Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€40.50
02.02.24
02.02.24
-
-
03.02.24
03.02.24
Could be worthwhile Investment >10% per year
Grifols S.A.
Start price
Target price
Perf. (%)
€9.54
09.01.24
09.01.24
-
09.01.25
09.01.25
24.03%
10.01.24
10.01.24
Could be worthwhile Investment >10% per year
Good culture
Few uniques
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€47.60
05.01.24
05.01.24
-
05.01.25
05.01.25
0.63%
05.03.24
05.03.24
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
High dividend yield expected
Good rating
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.96
02.01.24
02.01.24
€80.00
02.02.24
02.02.24
-6.29%
22.01.24
22.01.24
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.96
02.01.24
02.01.24
€80.00
02.02.24
02.02.24
-6.29%
22.01.24
22.01.24
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.96
02.01.24
02.01.24
€80.00
02.02.24
02.02.24
-6.29%
22.01.24
22.01.24
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€529.00
18.12.23
18.12.23
€558.00
18.12.24
18.12.24
6.62%
06.01.24
06.01.24
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€526.00
14.12.23
14.12.23
€558.00
14.12.24
14.12.24
0.57%
18.12.23
18.12.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market